Bupivacaine liposome (Exparel)

Small molecule

Also known as SKY0402

Approvedregulatory verdict

Evidence outlook

Approved: Acute Pain

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Acute Pain
NCT06235606 · The University of Hong Kong
2024-05-08 – 2026-02-05 · Acute Pain
What this study did
Other / comorbidity
NCT00813111 · Pacira Pharmaceuticals, Inc
2008-11 – 2009-02 · Pain
What this study did
NCT00745290 · Pacira Pharmaceuticals, Inc
2008-08 – 2009-02 · Postoperative Pain
What this study did
NCT00744848 · Pacira Pharmaceuticals, Inc
2008-08 – 2009-02 · Hemorrhoids
What this study did
Phase 2 (9)
Other / comorbidity
NCT04930887 · Stanford University
2023-02-01 – 2030-06 · Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
What this study did
NCT03504865 · Georgetown University
2019-07-01 – 2021-12 · Mastectomy, Breast Cancer
What this study did
NCT00485693 · Pacira Pharmaceuticals, Inc
2007-06 – 2009-08 · Postoperative Pain
What this study did
NCT00807209 · Pacira Pharmaceuticals, Inc
2008-12 – 2009-02 · Postoperative Pain
What this study did
NCT01206608 · Pacira Pharmaceuticals, Inc
2008-03 – 2008-12 · Postoperative Pain
What this study did
NCT00485433 · Pacira Pharmaceuticals, Inc
2007-06 – 2008-08 · Postoperative Pain
What this study did
NCT00529126 · Pacira Pharmaceuticals, Inc
2007-09 – 2008-07 · Postoperative Pain
What this study did
NCT01203644 · Pacira Pharmaceuticals, Inc
2004-12 – 2006-12 · Inguinal Hernia
What this study did
NCT01206595 · Pacira Pharmaceuticals, Inc
2005-03 – 2006-12 · Postoperative Pain
What this study did
Phase 1 (4)
Other / comorbidity
NCT01349140 · University of California, San Diego
2012-02 – 2012-04 · Healthy Volunteers
What this study did
NCT00812305 · Pacira Pharmaceuticals, Inc
2009-01 – 2009-08 · Pain, Hepatic Impairment
What this study did
NCT00806806 · Pacira Pharmaceuticals, Inc
2008-10 – 2009-02 · Postoperative Pain Management
What this study did
NCT00485667 · Pacira Pharmaceuticals, Inc
2007-06 – 2007-08 · Postoperative Pain
What this study did
Phase 4 (3)
Acute Pain
NCT05118399 · The University of Hong Kong
2021-11-15 – 2023-03-08 · Acute Pain
What this study did
Other / comorbidity
NCT06574022 · University of Cincinnati
2024-09-25 – 2026-12-01 · Mastectomy; Lymphedema, Breast Cancer
What this study did
NCT05494645 · St. Luke's Hospital, Pennsylvania
2022-03-01 – 2023-01-31 · Pain, Postoperative, Pain, Acute Postoperative, Ankle Fractures, Ankle Injuries and Disorders
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT03581539 · Indiana University
2018-05-22 – 2020-11-17 · Nephrectomy
What this study did

Competitive landscape

This drug's own stage for Acute Pain: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bupivacaine Liposome (Exparel): this drugApprovedSmall moleculeAmide Local Anestheticnot yet gradedNo reviewed efficacy summary in this indication
Suzetrigine (Journavx)ApprovedSmall moleculeVoltage-gated sodium channel NaV1.8Reliable signal
NCT05553366: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.6 units on a scale (Standard Error 6.3) | Suzetrigine (SUZ) 99.9 units on a scale (Standard Error 4.5)
NCT05558410: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.1 units on a scale (Standard Error 6.1) | Suzetrigine (SUZ) 118.4 units on a scale (Standard Error 4.3)
HRS-2129
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bupivacaine liposome (Exparel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Phase 2Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal HemicraniaRecruiting
Est. primary completion 2028-06 · NCT04930887 · CT.gov ↗
What to watch

See the full readout calendar ↗